Jul 15, 2025
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
Jul 14, 2025
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst(TM) Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Jul 14, 2025
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Jul 09, 2025
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
Jun 20, 2025
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
Jun 09, 2025
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
May 28, 2025
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
May 16, 2025
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst(TM) Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
May 15, 2025
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY(TM) (crinecerfont)
May 08, 2025
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst(TM) Pediatric Study Demonstrating CRENESSITY(TM) Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
May 06, 2025
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
May 05, 2025
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
May 05, 2025
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
Apr 30, 2025
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Apr 24, 2025
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
Apr 04, 2025
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Mar 17, 2025
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
Mar 11, 2025
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
Mar 05, 2025
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Feb 25, 2025
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March